The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
The Blimp1–Bcl6 axis is critical to regulate osteoclast differentiation and bone homeostasis
Open accessAbstract
Controlling osteoclastogenesis is critical to maintain physiological bone homeostasis and prevent skeletal disorders. Although signaling activating nuclear factor of activated T cells 1 (NFATc1), a transcription factor essential for osteoclastogenesis, has been intensively investigated, factors antagonistic to NFATc1 in osteoclasts have not been characterized. Here, we describe a novel pathway that maintains bone homeostasis via two transcriptional repressors, B cell lymphoma 6 (Bcl6) and B lymphocyte–induced maturation protein-1 (Blimp1). We show that Bcl6 directly targets ‘osteoclastic’ molecules such as NFATc1, cathepsin K, and dendritic cell-specific transmembrane protein (DC-STAMP), all of which are targets of NFATc1. Bcl6-overexpression inhibited osteoclastogenesis in vitro, whereas Bcl6-deficient mice showed accelerated osteoclast differentiation and severe osteoporosis. We report that Bcl6 is a direct target of Blimp1 and that mice lacking Blimp1 in osteoclasts exhibit osteopetrosis caused by impaired osteoclastogenesis resulting from Bcl6 up-regulation. Indeed, mice doubly mutant in Blimp1 and Bcl6 in osteoclasts exhibited decreased bone mass with increased osteoclastogenesis relative to osteoclast-specific Blimp1-deficient mice. These results reveal a Blimp1–Bcl6–osteoclastic molecule axis, which critically regulates bone homeostasis by controlling osteoclastogenesis and may provide a molecular basis for novel therapeutic strategies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph node organogenesis.
Kong, Y.-Y., Yoshida, H., Sarosi, I., Tan, H.-L., Timms, E., Capparelli, C., Morony, S., Oliveira-dos-Santos, A. J., Van, G., Itie, A., et al. (1999) · Nature · doi:10.1038/16852 · Cited by 3,351 · cited 2×
“Osteoclasts originate from BM–derived monocyte/macrophage precursor cells of hema topoietic origin and are differentiated by sig naling through the receptor activator of NFB ligand (RANKL; Kong et al., 1999).”
BackgroundTakayanagi, H., Kim, S., Koga, T., Nishina, H., Isshiki, M., Yoshida, H., Saiura, A., Isobe, M., Yokochi, T., Inoue, J.-I., et al. (2002) · Developmental Cell · doi:10.1016/s1534-5807(02)00369-6 · Cited by 2,701 · cited 5×
“RESULTS Bcl6 is a negative regulator of osteoclastogenesis RANKL stimulates osteoclastogenesis by activating NFATc1 (Takayanagi et al., 2002; Koga et al., 2004; Sato et al., 2006; JEM VOL. 207, April 12, 2010 Article 753 RANKL, Blimp1 was absent from the Bcl6 promoter, but was recruited there by…”
BackgroundInfluentialA homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function.
Anderson, D. M., Maraskovsky, E., Billingsley, W. L., Dougall, W. C., Tometsko, M. E., Roux, E. R., Teepe, M. C., DuBose, R. F., Cosman, D., & Galibert, L. (1997) · Nature · doi:10.1038/36593 · Cited by 2,290
Therapeutic Approaches to Bone Diseases
Rodan, G. A., & Martin, T. J. (2000) · Science · doi:10.1126/science.289.5484.1508 · Cited by 1,767 · cited 1×
“Dysregulation of osteoclast differentiation or function disrupts mainte nance of bone homeostasis, which in turn leads to pathogenic conditions such as osteoporosis, rheumatoid arthritis, lytic bone metastases, or Paget’s bone disease (Rodan and Martin, 2000).”
BackgroundRANK is essential for osteoclast and lymph node development.
Dougall, W. C., Glaccum, M., Charrier, K., Rohrbach, K., Brasel, K., De Smedt, T., Daro, E., Smith, J., Tometsko, M. E., Maliszewski, C. R., et al. (1999) · Genes & Development · doi:10.1101/gad.13.18.2412 · Cited by 1,478
DC-STAMP is essential for cell–cell fusion in osteoclasts and foreign body giant cells
Yagi, M., Miyamoto, T., Sawatani, Y., Iwamoto, K., Hosogane, N., Fujita, N., Morita, K., Ninomiya, K., Suzuki, T., Miyamoto, K., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050645 · Cited by 890
Self-citationAutoamplification of NFATc1 expression determines its essential role in bone homeostasis
Asagiri, M., Sato, K., Usami, T., Ochi, S., Nishina, H., Yoshida, H., Morita, I., Wagner, E. F., Mak, T. W., Serfling, E., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20051150 · Cited by 849
Matsumoto, M., Kogawa, M., Wada, S., Takayanagi, H., Tsujimoto, M., Katayama, S., Hisatake, K., & Nogi, Y. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m408795200 · Cited by 436 · cited 2×
“Blimp1 expression 756 Blimp1–Bcl6 axis influences bone mass | Miyauchi et al. NFATc1 (Matsumoto et al., 2004; Asagiri et al., 2005; Yagi et al., 2007), was markedly inhibited in Blimp1 cKO osteo clasts (Fig.”
Background
Cited by
Regulation of NFATc1 in Osteoclast Differentiation
Kim, J. H., & Kim, N. (2014) · Journal of Bone Metabolism · doi:10.11005/jbm.2014.21.4.233 · Cited by 570
“In addition, the Ca2+ chelator BAPTA-AM suppresses osteoclast differentiation mediated by RANKL through the inhibition of nuclear localization of NFATc1.”
BackgroundInfluentialOsteoimmunology: The conceptual framework unifying the immune and skeletal systems
Okamoto, K., Nakashima, T., Shinohara, M., Negishi-Koga, T., Komatsu, N., Terashima, A., Sawa, S., Nitta, T., & Takayanagi, H. (2017) · Physiological Reviews · doi:10.1152/physrev.00036.2016 · Cited by 534
Advances in the regulation of osteoclasts and osteoclast functions
Boyce, B. F. (2013) · Journal of Dental Research · doi:10.1177/0022034513500306 · Cited by 457
Recent advances in osteoclast biology
Ono, T., & Nakashima, T. (2018) · Histochemistry and Cell Biology · doi:10.1007/s00418-018-1636-2 · Cited by 384
New insights into osteoclastogenic signaling mechanisms
Nakashima, T., Hayashi, M., & Takayanagi, H. (2012) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2012.05.005 · Cited by 342
The role of cytokines in inflammatory bone loss
Souza, P. P. C., & Lerner, U. H. (2013) · Immunological Investigations · doi:10.3109/08820139.2013.822766 · Cited by 269
The prdm family: expanding roles in stem cells and development
Hohenauer, T., & Moore, A. W. (2012) · Development · doi:10.1242/dev.070110 · Cited by 265
“Prdm16 was originally identified as a leukaemogenic oncogene (Mochizuki et al., 2000; Morishita, 2007; Nishikata et al., 2003).”
BackgroundZhao, B., Grimes, S. N., Li, S., Hu, X., & Ivashkiv, L. B. (2012) · Journal of Experimental Medicine · doi:10.1084/jem.20111566 · Cited by 182
Zhao, B., & Ivashkiv, L. B. (2011) · Arthritis Research & Therapy · doi:10.1186/ar3379 · Cited by 144
“Recently, the transcriptional repressor Blimp1 (B lymphocyteinduced maturation protein-1), which is induced by NFATc1 in response to RANKL stimulation, was shown to suppress the expression of IRF-8, MafB [63] and Bcl6 [ 60 ] (Figure 2). Blimp1 defi ciency attenuates downregulation of IRF-8, MafB and Bcl6 expression af…”
InfluentialRole and Regulation of Transcription Factors in Osteoclastogenesis
Jiang, T., Xia, T., Qiao, F., Wang, N., Jiang, Y., & Xin, H. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242216175 · Cited by 60
“Epigenetic regulation of osteoclastogenesis plays an important role, and the exertion of this role is closely related to the regulation of osteoclast transcription factor expression.”
BackgroundCarey, H. A., Hildreth, B. E., Geisler, J. A., Nickel, M. C., Cabrera, J., Ghosh, S., Jiang, Y., Yan, J., Lee, J., Makam, S., et al. (2018) · Bone Research · doi:10.1038/s41413-018-0011-1 · Cited by 40
Metadata
- Authors
- Miyauchi, Y., Ninomiya, K., Miyamoto, H., Sakamoto, A., Iwasaki, R., Hoshi, H., Miyamoto, K., Hao, W., Yoshida, S., Morioka, H., Chiba, K., Kato, S., Tokuhisa, T., Saitou, M., Toyama, Y., Suda, T., & Miyamoto, T.
- Venue
- Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2010-04-05
- Volume
- 207
- Issue
- 4
- Pages
- 751-762
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- OpenAlex
- W2146565196
- Cited by
- 199
- References
- 8
- FWCI
- 5.55
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.